Fixed dose combinations of ace inhibitors

British Journal of Clinical Practice

Volumn 50, Issue 8, 1996, Pages 454-465

  Rangoonwaia, B ^a   Schulz, W ^a   Bauer, B ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CLINICAL TRIAL; DRUG COMBINATION; HUMAN; HYPERTENSION; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION;

EID: 0030339227     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150: 1175-1183.
2. WHO/ISH Guidelines Subcommittee. Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. J Hypertens 1993; 11:905-918.
3. National Institutes of Health US National Heart Lung and Blood Institute. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood pressure. NIH Publication No 93-1088, January 1993.
4. MacConnachie AM, MacLean D. Low dose combination antihypertensive therapy: additional efficacy without additional adverse effects? Drug Safety 1995; 12: 85-90.
5. Messerli FH. Combination therapy in hypertension. J Hum Hypertens 1992;6(Suppl2):S19-S21.
6. Croog SH, Levine S, Testa MA. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1987; 314: 1657-1664.
7. Jorgensen H, Anderssen N, Silsand T, Petersen LE. Long-term treatment with slow-release frusemide in the treatment of hypertension. J Int Med Res\ 989; 17: 552-559.
8. Verho M, Rangoonwala B, Dois W et al. Piretanide, a potassium stable diuretic in the treatment of essential hypotension. Eur J Clin Pharmacol 1984; 27: 407-414.
9. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996; 275: 1507-1513.
10. Genthon R and the Athes Study Group. Study of the efficacy and safety of the combination ramipril 25 mg plus hydrochlorothiazide 125 mg in patients with mild-to-moderate hypertension. Int J Clin Pharmacol Res 1994; 14: 1-9.
11. Chrysant SG for the Lisinopril-Hydrochlorothiazide Group. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. Arch Intern Med 1994; 154: 737-743.
12. Hart W. Lisinopril-hydrochlorothiazide combination compared with the monoconiponents in elderly hypertensive patients. J Hum Hypertens 1991; 5(Suppl 2): 85-89.
13. Lang H. The results of a large multicentre study comparing low-dose lisinopril-hydrochlorothiazide with the monoconiponents. J Hum Hvpertens 1991 ; 5(Suppl 2): 73-76.
14. Mersey J, D'Hemecourt P, Blaze K. Once-daily fixed combination of captopril and hydrochlorothiazide as first line therapy for mild to moderate hypertension. Curr TherRes 1993; 53: 502-512.
15. Lenz T, Schulte K-L, Wagner B et al. Quinapril hydrochlorothiazide and combination in patients with moderate to severe hypertension. Eur Heart J 1994; 15: 940-946.
16. Scholze J, Breitstadt A, Cairns V et al. Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens 1993; 11: 217-221.
17. Canter D, Frank GJ, Knapp LE et al. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. J Hum Hypertens 1994; 8: 155-162.
18. Heidbreder D, Froer KL, Bauer B et al. Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension. Part 2: An open long-term study of efficacy and safety. Clin Cardiol 1993; 16: 47-52.
19. Homuth V, Faulhaber H-D. Loose U et al. Usefulness of piretanide plus ramipril for systemic hypertension: a multicenter trial. Am J Cardiol 1993; 72: 666-671.
20. Carré A, Zannad F, Vasmant D. The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension. Clin Physiol Biochem 1992; 9: 105-112.
21. Amery A, Kiowski W, Löffler K et al. Double-blind comparison of ramipril, piretanide and the combined therapy in hypertensive patients. Presented at the 15th Scientific Meeting of the International Society of Hypertension, Melbourne, March 1994.
22. Yasky J. Evaluation of a new angiotensin converting enzyme inhibitor ramipril alone and with piretamide. Presented at the llth Scientific Meeting of the International Society of Hypertension, Heidelberg, September 1986.
23. Middlemost SJ, Tager R, Davis J, Sareli P. Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. Am J Cardiol 1994; 73: 1092-1097.
24. Heidbreder D, Froer K-L, Breitstadt A et al. Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1 -A, double-blind comparative multicenter study in nonresponders to ramipril monotherapy. Clin Cardiol 1992; 15: 904-910.
25. Strocchi E, Bossini A, Ranierei G, Filitti V. Efficacy and tolerability of enalapril 20 mg/hydrochlorothiazide 125 mg combination therapy in essential hypertension. Clin Ther 1991; 13: 737-746.
26. Lacoucière Y, Poirier L, Provencher P, Guivarch PH. Once vs twice daily administration of a fixed combination of captopril plus hydrochlorothiazide in essential hypertension: a double-blind crossover study in known responders to a standard combination. Br J Clin Pharmacol 1991 ; 32: 115-119.
27. The Enalapril-Hydrochlorothiazide in Essential Hypertension Canadian Working Group. Enalapril and enalapril-hydrochlorothiazide in the treatment of essential hypertension. Clin Ther 1993; 15: 364-373.
28. Pathé M. Lisinopril-hydrochlorothiazide combination vs lisinopril for the treatment of hypertension. J Hum Hypertens 1991 ; 5(Suppl 2): 53-54.
29. Kiowski W, Krüger B, Erne P. Effects of 2 months antihypertensive therapy with a diuretic, and angiotensin-converting enzyme inhibitor and their combination on left ventricular mass in primary hypertension: a pilot study. Presented at the 4th International Conference on Diuretics, Boca Raton, October 1992.
30. Graham RD. Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. J Hum Hypertens 1991 ; 5(Suppl 2): 59-61.
31. Fogari R, Zoppi A, Tettamanti F et al. Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of benazepril 20 mg plus hydrochlorothiazide 25 mg fixed combination as compared to captopril 25 mg plus hydrochlorothiazide 25 mg fixed combination in treating mild to moderate hypertension: a double-blind within-patient placebo-controlled study, J Cardiovasc Pharmacol 1994; 24: 687-693.
32. McGrath BP. Matthews PC, Louis W et al. Double-blind study of dilevalol and captopril both in combination both in combination with hydrochlorothiazide in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1990; 16: 831-838.
33. Elliott WJ, Polascik TB, Murphy MB. Equivalent antihypertensive effects of combination therapy using diuretic + calcium antagonist compared with diuretic + ACE inhibitor. J Hum Hypertens 1990; 4:717-723.
34. Letellier P, Overlack A, Agnes E, Desche P. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. J Hum Hvperten.ï 1994; 8: 145-149.
35. Van Hamersvelt HW, Wetzels JFM, Kloke HJ et al. Angiotensin converting enzyme inhibition does not prevent the natriuretic effect of felodipine. J Cardiovasc Pharmacol 1993; 21: 471-477.
36. Bainbridge AD, MacFadyen RJ, Stark S et al. The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension. Br J Clin Pharmacol 1993; 36: 323-330.
37. Jungmann E. Haak T, Rademacher M. Renal responses to insulininduced hypoglycemia in healthy volunteers: effect of the converting enzyme inhibitor ramipril and of the calcium antagonist felodipine. Nieren Hochdruckkrankh 1994; 23: 119-124.
38. Sun JX, Cipriano A. Chan K, John VA. Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. Eur J Clin Pharmacol 1994; 47: 285-289.
39. Bainbridge AD, MacFadyen RJ, Stark S et al. The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension. Br J Clin Pharmacol 1993; 36: 323-330.
40. Capuccio FP, Markandu ND, Singer DRJ, MacGregorGA. Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J Hypertens 1993; 11: 839-847.
41. Morgan TO, Anderson A, Jones E. Comparison and interaction of low dose felodipine and enalapril in the treatment of essential hypertension in elderly subjects. Am J Hypertens 1992; 5: 238-243.
42. Scholze J, Bauer B. Massaro J et al. Ramipril and felodipine extended release combination therapy in hypertension: a clinical trial of factorial design. Eur Heart J 1994; 15(Suppl): 533.
43. Hoechst Pharmaceuticals, Hoe 9869. Combination of ramiprilfelodipine. Data on file.
44. Hammond JJ, Anderson A, Morgan TO. Ramipril: effective 24-hour awake and asleep blood pressure control. Presented at the 15th Scientific meeting of the International Society of Hypertension. Melbourne, March 1994.
45. Fitscha P, Meisner W, Hitzenberger G. Evaluation of irsadipine and captopril alone or in combination for the treatment of hypertension. J Cardiovasc Pharmacol 1991; 18(Suppl): S12-S14.
46. Maclean D. Combination therapy with amlodipine and captopril for resistant systemic hypertension. Am J Cardiol 1994; 73: 55A-58A.
47. Lüscher TF, Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. J Cardiovasc Pharmacol 1993; 21: 305-309.
48. Levine JH. Ferdinand KC, Cargo P et al. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens 1995: 8: 494-499.
49. Di Somma S. Carotenuto A, de Divitiis M et al. Favourable interaction of calcium antagonist plus ACE inhibitor on cardiac haemodynamics in treating hypertension: rest and effort evaluation. J Hum Hypertens 1995; 9: 163-168.
50. Singer RJ, Markandu ND, Cappuccio FP, MacGregor GA. Studies of captoril alone and in combination with the benzothiazepine diltiazem or the dihydropyridine nifedipine in treating essential hypertension. J Cardiovasc Phannacol 1991; 18(suppl 9): S51-S54.
51. Frishmann WH, Ram CVS. McMahon FG et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomised, double-blind. placebo-controlled, parallel group study. J Clin Pharmacol 1995; 35: 1060-1066.
52. Krusell LR, Sihm I, Jespersen LT et al. Combined actions of isradipine and captopril on renal function in hypertension. J Hum Hvpertens 1992; 6:401-407.
53. Pedersen MM, Hansen KW. Schmilz A et al. Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy. Kidney Int 1992; 41: 883-890.
54. Becker RHA, Baldes L. Treudler M. Prevention of progressive proteinuria with felodipine and ramipril in rats with remnant kidneys. Nieren Hochdruckkrankh 1991; 20: 584-587.
55. Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism 1996; 45(5): 535-541.
56. Jungmann E. Haak T, Rademacher M. Renal responses to insulininduced hypoglycaemia in healthy volunteers: effect of the converting enzyme inhibitor ramipril and of the calcium antagonist felodipine. Nieren Hochdruckkrankh 1994; 23: 119-124.
57. Stornello M. Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 1989; 14: 851-855..
58. Mayet J, Stanton AV, Sinclair A-M et al. The effects of antihypertensive therapy on carotid vascular structure in man. Cardiovasc Res 1995; 30: 147-150.
59. Hansson L. Beta-blockers with ACE inhibitors - a logical combination? J Hum Hypertens 1989; 3(Suppl 1): 97-100.
60. van Griensven JMT, Seibert-Grafe M, Schoemaker HC et al. The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol. Eur J Clin Pharmacol 1993; 45: 255-260.
61. Erb KA, Breithaupt K, Beiz GG. Beta-blockers and ACE-inhibitors further evidence for therapeutic benefit of this combination in hypertension. J Hum Hypertens 1990; 4: 63-65.
62. Soininen K, Gerlin-Piira L, Suihkonen T et al. A study of the effects of lisinopril when used in addition to atenolol. J Hum Hvpertens 1992; 6:321-324.
63. Hannson L on behalf of the Swedish Lisinopril Study Group. Lisinopril combined with atenolol in the treatment of hypertension. J Cardiovasc Pharmacol 1991; 18:457-461.
64. Ketelhut R, Franz I, Behr W et al. Preserved ventricular pump function after a marked reduction of left ventricular mass. J Am Coll Cardiol 1992; 20: 864-868.
65. Kaplan NM. Clinical Hypertension. 5th edition. Baltimore: Williams andWilkins, 1990.
66. Meredith PA. Elliot! HL, Keiman AW, Reid JL. Application of pharmacokjnetic-pharmacodynamic modeling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers, J Cardiovasc Pharmacol 1985; 7: 532-537.
67. Batey DM, Nicholich MJ, Lassen VI et al. Prazosin versus hydrochlorothiazide as initial antihypertensive therapy in black versus white patients. Am J Med 1989; 86(suppl IB): 74-78.
68. Stokes GS, Weber MA. Prazosin: preliminary report and comparative studies with other antihypertensive agents. Br Med J 1974: 2: 298-300.
69. Tolseth T. Westlie L, Daae L. A long-term study of atenolol and doxazosin in mild and moderate hypertension. J Hum Hvpertens 1990; 4(suppl3): 39-44.
70. Sica DA. Fixed-dose combination antihypertensive drugs - do they have a role in rational therapy? Drugs 1994; 48: 16-24.